Aura Biosciences, Inc.
$6.88
-0.29%Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -3.9).
Valuation inputs: P/E -3.9, earnings yield N/A, momentum -0.3%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -77.6%, ROIC -73.1%).
Profitability stack: net margin 0.0%, ROE -77.6%, ROIC -73.1%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +19.2%, momentum -0.3%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Aura Biosciences, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Aura Biosciences, Inc. Fair Value Envelope
No Revenue Data
AURA has not reported any revenue values in the available annual periods.
Aura Biosciences, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
AURA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
AURA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
AURA has not reported any net profit margin values in the available annual periods.
Aura Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Declining FCF warrants attention. Investigate whether due to temporary factors or fundamental deterioration.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Aura Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Aura Biosciences, Inc. Street Expectations Map
Wall Street analysts project that AURA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 17.00, with estimates ranging from a low of 17.00 to a high of 17.00.
The consensus 1-year price target stands at 17.00, with estimates ranging from a low of 17.00 to a high of 17.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Aura Biosciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $315K and sold $39.98M worth of AURA shares, resulting in $39.67M of net selling activity.
3 Months
0
0.00
6.9M
39.13M
-39.1M
-$39.13M
3-6 Months
0
0.00
123.1K
618.78K
-619K
-$619K
6-9 Months
0
0.00
39.2K
233.15K
-233K
-$233K
9-12 Months
51.0K
315.18K
1.1K
3.46K
+312K
+$312K
Top Buyers
Mattessich Antony C.
Director
$105K
Srivastava Sapna
Director
$105K
Johnson David Michael
Director
$105K
Top Sellers
Matrix Capital Management Company, Lp
10 Percent Owner
$39.04M
De Los Pinos Elisabet
Director, Officer: See Remarks
$381K
Hopkins Janet Jill
Officer: Chief Medical Officer
$196K
Plavsic Mark
Officer: Chief Technology Officer
$158K
Kilroy Conor
Officer: See Remarks
$143K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $39.67M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
AURA has not reported any dividend yield values in the available annual periods.
aura Dividend History
Learning Layer
Related Guides
Build conviction on AURA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.